Loading clinical trials...

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE) | Clinical Trials | Clareo Health

RECRUITINGNA

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)

FASCINATE: FeASibility of Cbct-guIded oNline Adaptive radioThErapy

NCT06691776•The Netherlands Cancer Institute

Summary

The accuracy of radiotherapy can be increased by correcting for geometric uncertainties and changes between radiotherapy fractions. These corrections are currently done with online adaptive treatment on a specialized linear accelerator (linac) for a small subset of patients. However, patients currently treated on a standard linac could also benefit from online adaptive radiotherapy. The objective is to determine the feasibility of online CBCT-guided adaptive radiation therapy on a standard Elekta linac.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient, age ≥ 18 years, referred for a radiotherapy schedule as described in one of the cohorts.
•WHO performance score 0-3.
•Provision of signed, written and dated IC prior to any study specific procedures.
•Accepted for radiotherapy of the prostate and pelvic lymph node areas.
•Pathology-proven prostate cancer.
•cT1-4
•cN1 on PSMA-PET/CT or pN1 based on node biopsy, SN-procedure or lymph node dissection.
•cM0 on PSMA-PET/CT (except for patients with M1a disease who are still considered for radiotherapy of the prostate and pelvic lymph node areas).
•Accepted for radiotherapy of the cervix (with or without chemotherapy) and pelvic lymph node areas (25 fractions, followed by either a brachytherapy or external radiotherapy boost).
•Pathology-proven cervical cancer.
+15 more criteria

Exclusion Criteria

•Patients who are pregnant.
•Specific for prostate cohort:
•Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).
•Severe lower urinary tract symptoms that could make the longer treatment time problematic (according to judgement of treating physician).
•Specific for cervical cohort:
•\- Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).
•Specific for bladder cohort:
•Patients with a medical condition that severely compromises CBCT image quality (mainly hip prostheses).
•Severe lower urinary tract symptoms that could make the longer treatment time problematic (according to judgement of treating physician).
•Specific for lung cohort:
+4 more criteria

Locations (1)

Antoni van Leeuwenhoek Hospital

Amsterdam, Netherlands

Key Dates

Start Date

August 29, 2023

Primary Completion Date

October 1, 2028

Completion Date

December 1, 2028

Last Updated

August 1, 2025

Enrollment

100

ESTIMATED participants

Conditions

Prostate CancerCervical CancerBladder CancerLung CancerHead and Neck Cancer

Interventions

online CBCT-guided adaptive radiation therapy using a new software

DEVICE

Contacts

Evelien Schouten, MSc

CONTACT

+31205129140 ev.schouten@nki.nl

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITING

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT00026884

Malignant NeoplasmsHereditary Neoplastic Syndromes+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes